Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy
R Haas, R Kronenwett, G Sczakiel, A Hochhaus… - … and Molecular Therapy, 1998 - Springer
… reduced considerably if patients are monitored by molecular … , or competitive reverse
transcriptase polymerase chain reaction (… trial of interferon-alpha n 1 for chronic myeloid …
transcriptase polymerase chain reaction (… trial of interferon-alpha n 1 for chronic myeloid …
Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha.
HC Duba, S Peter, W Hilbe… - International …, 1999 - spandidos-publications.com
… be efficient in monitoring the percentage of Ph cells in patients … survival in chronic myelogenous
leukemia after cyto genetic … therapy by competitive polymerase chain reaction. Blood 87: …
leukemia after cyto genetic … therapy by competitive polymerase chain reaction. Blood 87: …
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …
P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - nature.com
… of individual patients to treatment or to evaluate the efficacy of a particular … in chronic
myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. …
myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. …
Monitoring of minimal residual disease in chronic myeloid leukemia
S Faderl, A Hochhaus… - Hematology/Oncology …, 2004 - hemonc.theclinics.com
… ) a shift from using qualitative polymerase chain reaction (PCR) … Competitive polymerase
chain reaction to estimate the … after interferon-alpha therapy for chronic myelogenous leukemia: …
chain reaction to estimate the … after interferon-alpha therapy for chronic myelogenous leukemia: …
Molecular monitoring of chronic myeloid leukemia
T Hughes, S Branford - Seminars in hematology, 2003 - Elsevier
… and lower progression rates than interferon-alpha. However, … (FISH) and qualitative
polymerase chain reaction (PCR) have … The level of BCR-ABL measured by competitive Q-PCR is …
polymerase chain reaction (PCR) have … The level of BCR-ABL measured by competitive Q-PCR is …
Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia
F Campanini, MA Santucci, L Pattachini… - …, 2001 - haematologica.org
… their resistance to interferon-alpha or tyrosine kinase inhibitors. … in liquid culture or plating
efficiency in semisolid culture medium (… monitoring of residual disease in chronic myelogenous …
efficiency in semisolid culture medium (… monitoring of residual disease in chronic myelogenous …
[HTML][HTML] Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction
… was to evaluate the efficacy of a treatment protocol and to … patients were pretreated with
busulfan or interferon-alpha, … A hypothetical mechanism could be competition with IM for a …
busulfan or interferon-alpha, … A hypothetical mechanism could be competition with IM for a …
A guide to the use of interferon-alpha in the management of chronic myelogenous leukaemia
J Cortes, S O'Brien - BioDrugs, 2000 - Springer
… Patients should be monitored closely with cytogenetic and possibly other analyses such as
fluorescent in situ hybridisation (FISH) and polymerase chain reaction (… Although the efficacy …
fluorescent in situ hybridisation (FISH) and polymerase chain reaction (… Although the efficacy …
Practical monitoring of chronic myelogenous leukemia: when to change treatment
G Saglio, C Fava - Journal of the National Comprehensive Cancer …, 2012 - jnccn.org
… real-time quantitative polymerase chain reaction (RQ-PCR) … , whose efficacy as second-line
therapy in patients with imatinib-… of any products discussed in this article or their competitors. …
therapy in patients with imatinib-… of any products discussed in this article or their competitors. …
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia
J Kaeda, A Chase, JM Goldman - Acta haematologica, 2002 - karger.com
… , the reverse-transcriptase polymerase chain reaction (RT-… In the early 1990s a number of
groups developed competitive … of interferon-alpha in the treatment of chronic myeloid leukemia…
groups developed competitive … of interferon-alpha in the treatment of chronic myeloid leukemia…